XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Passes Above Fifty Day Moving Average – What’s Next?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)’s share price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.57 and traded as high as $2.89. XTL Biopharmaceuticals shares last traded at $2.89, with a volume of 7,504 shares.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

XTL Biopharmaceuticals Stock Performance

The business has a 50 day moving average of $2.57 and a two-hundred day moving average of $2.86. The stock has a market capitalization of $6.36 million, a PE ratio of -4.52 and a beta of 1.45.

XTL Biopharmaceuticals (NASDAQ:XTLB) last released its quarterly earnings results on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) EPS for the quarter. The business had revenue of ($0.26) million for the quarter.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.